

REMARKS

Claims 25-37 are now pending, with Claim 25 being the sole independent claim.

Claims 1-24 have been canceled without prejudice to or disclaimer of the subject matter recited therein.

Claims 25-37 have been added. Support for the sequence identities recited in Claims 26-28 is found at least in the paragraph beginning on line 15 of page 7 of the specification. Support for the use of the term "recombinant" in Claims 19, 21, 23 and 24 is found at least in the paragraph beginning on line 32 of page 11 of the specification. Support for Claims 35-37 are found at least in Examples 4-5, pages 19-23 of the specification. No new matter has been added.

The specification has been amended at two locations to remove reference to the following URL: www.ncbi.nlm.nih.gov/BLAST/.


RESPONSE TO RESTRICTION REQUIREMENT

In response to the Restriction Requirement in the Office Action mailed March 11, 2003, Applicants hereby elect, without traverse, Group I (drawn to a polynucleotide, chimeric gene, host cell, virus, expression cassette and first method of using) and Group A (drawn to a polynucleotide of SEQ ID NO:1 or corresponding polypeptide of SEQ ID NO:2). Applicants believe new claims 25-34 and 36-37 to be directed to Group I. Applicants also believe new claim 35 to be directed to Group I.

Please charge any fees or credit any overpayment of fees which are required in connection herewith to Deposit Account No. 04-1928 (E. I. du Pont de Nemours and Company).

In view of the foregoing, allowance of the above-referenced application is respectfully requested.

Respectfully submitted,



J. KENNETH JOUNG
ATTORNEY FOR APPLICANTS
REGISTRATION NO. 41,881
TELEPHONE: 302-992-4929
FACSIMILE: 302-892-1026

Dated: 10 July 2003